Publications

1. Final report – Case study phase ROR DGM

   The Dutch National Health Care Institute presents its vision on data availability in healthcare, based on 4 completed case ...

   Report | 30-11-2023

2. GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertension

   The National Health Care Institute has assessed whether latanoprost in combination with netarsudil (Roclanda®) can be included in ...

   Report | 22-11-2023

3. Package advice lock procedure product emicizumab (Hemlibra®) for the treatment of moderate haemophilia A

   The National Health Care Institute has assessed whether emicizumab (Hemlibra®) can be reimbursed from the basic health care ...

   Report | 16-11-2023

4. Orphan drug arrangement givosiran (Givlaari®) for the treatment of acute hepatic porphyria

   Agreements have been made to promote appropriate use of givosiran (Givlaari®) as treatment of acute hepatic porphyria, a rare ...

   Publication | 24-10-2023

5. Conditional inclusion procedure for medicinal products

   This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.

   Publication | 29-09-2023

6. Advice on a possible candidate for the conditional inclusion of teduglutide (Revestive®)

   The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate teduglutide (Revestive®) ...

   Report | 21-09-2023

7. Package advice for the lock procedure medicinal product zanubrutinib (Brukinsa®) for the treatment of chronic lymphocytic leukaemia (CLL)

   The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...

   Report | 31-08-2023

8. GVS advice fenfluramine (Fintepla®) for the treatment of epileptic seizures in Dravet Syndrome or Lennox-Gastaut Syndrome

   The National Health Care Institute has assessed whether fenfluramine (Fintepla®) can be included in the Medicine Reimbursement ...

   Report | 31-08-2023

9. GVS advice midazolam (Midazolam Xiromed®) for the treatment of epilepsy

   The National Health Care Institute has assessed whether oromucosal administration of midazolam (Midazolam Xiromed®) can be ...

   Report | 22-08-2023

10. GVS advice for tirzepatide (Mounjaro®) for the treatment of adults with type 2 diabetes mellitus without a very high risk of cardiovascular disease

    The National Health Care Institute has assessed whether tirzepatide (Mounjaro®) can be included in the Medicine Reimbursement ...

    Report | 14-08-2023